A Pharmacogenomic approach for the identification and validation of genetic markers behind CDK4 amplification leading to Cancer
Author(s):
Divya V, VL Pushpa, Sunitha VR, S Sarithamol, Suchitra Surendran and Manoj KB
Abstract:
Cyclin Dependent Kinase 4 gene has been identified as the key regulator in many types of cancerous tumors. Identification of genetic involvement behind the expression of this gene is therefore a promising field while developing suitable treatment measures for cancers. Pharmacogenomic study of Cyclin Dependent Kinase 4 has revealed the genes associated with CDK4 expression and different epigenetic as well as Metagenomic influences that encourage CDK4 expression. This helps to identify the deleterious single nucleotide polymorphisms related to this gene. The study also focused to understand the structure of corresponding CDK4 protein and developed a high quality homology model of the protein so as to facilitate structure based drug discovery of CDK4 inhibitor.
How to cite this article:
Divya V, VL Pushpa, Sunitha VR, S Sarithamol, Suchitra Surendran, Manoj KB. A Pharmacogenomic approach for the identification and validation of genetic markers behind CDK4 amplification leading to Cancer. Pharma Innovation 2019;8(2):142-149.